Does HRT still raise breast cancer risk?

Short answer: Yes, certain types of HRT can slightly raise breast cancer risk, but not all forms do. According to the WHI long-term follow-up data, estrogen-only therapy does not increase breast cancer risk, and some analyses show a slightly lower risk. The small increase observed in large studies comes only from long-term use of combined HRT (estrogen plus a progestogen), and even then, the rise is modest and reversible after stopping.

What the evidence shows

Per published clinical guidelines, the best data come from long-term follow-up of large studies. These consistently show:

• Estrogen-only therapy (used when a woman has no uterus) does not increase breast cancer risk, according to the WHI long-term follow-up data. Some analyses even show a slightly lower risk in this group.
• Combined therapy (estrogen plus a progestogen) can create a small increase in breast cancer risk after several years of continuous use, per published clinical guidelines.
• According to current NAMS guidelines, the increase is dose-related and time-related—meaning higher dose and longer use are associated with slightly more risk.
• According to the WHI long-term follow-up data, once a woman stops combined HRT, the small added risk gradually returns toward baseline.

How large is the risk in context

Per published clinical guidelines, in an average group of 1000 women aged 50–60 who do not use HRT, about 23 will develop breast cancer over a defined follow-up period. If the same group uses combined HRT for approximately 5 years, the number rises by about 4–5 extra cases. Current clinical practice considers this a modest increase that must be weighed against symptom burden and other health factors on an individual basis.

Why estrogen alone differs

When the uterus has been removed, estrogen can be given by itself. According to current NAMS guidelines, without the added progestogen, breast tissue stimulation is lower, which is consistent with findings showing estrogen-only therapy does not raise breast cancer risk in this population.

Forms of hormones matter

Per published clinical guidelines, many patients now use transdermal estrogen (patch, gel) and body-identical micronized progesterone. These formulations appear to have a more favorable breast profile than older synthetic progestins. Some patients also use compounded preparations containing these same hormones.

Compounded medications are not FDA-approved. They have not been reviewed by the FDA for safety, effectiveness, or quality. FDA-approved medications should be considered first when commercially available options meet patient needs.

Important caveat regarding breast cancer history

Per FDA-approved prescribing information for estrogen/progestogen products, breast cancer history is listed as a contraindication. A prescriber must evaluate individual risk factors before considering any hormone therapy in this context. This evaluation cannot be performed through website content alone.

Factors that may influence risk

• Using the lowest effective dose, per current NAMS guidelines
• Choosing transdermal estrogen where clinically appropriate
• Using body-identical micronized progesterone if a progestogen is required
• Regular breast screening as recommended by a clinician
• Lifestyle measures (physical activity, limiting alcohol), per published clinical guidelines

Summary: According to current NAMS guidelines and the WHI long-term follow-up data, HRT does not carry a uniform breast cancer risk across all formulations. The only consistent increase identified in large studies comes from long-term combined therapy, and even that increase is small, depends on dose and duration, and declines after stopping. Modern transdermal and body-identical formulations appear to carry a more favorable profile, though individual assessment remains essential.

Whether HRT is appropriate depends on individual health factors, including personal and family history of breast cancer, duration of planned use, and overall risk-benefit profile. A prescriber should determine the best approach based on a patient's complete medical history.